Ficlatuzumab
HPV-negative Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Key Facts
About AVEO Oncology
AVEO Oncology is a clinical-stage biopharmaceutical company specializing in targeted cancer therapies, operating as a U.S. subsidiary of South Korea's LG Chem. The company has one FDA-approved product, FOTIVDA for renal cell carcinoma, and a diverse early-to-mid-stage pipeline focused on monoclonal antibodies and novel mechanisms. Its business model centers on in-licensing, co-development, and commercialization, aiming to grow into a global oncology leader by leveraging LG Chem's resources and strategic partnerships.
View full company profileAbout AVEO Oncology
AVEO Oncology is a clinical-stage biopharmaceutical company specializing in targeted cancer therapies, operating as a U.S. subsidiary of South Korea's LG Chem. The company has one FDA-approved product, FOTIVDA for renal cell carcinoma, and a diverse early-to-mid-stage pipeline focused on monoclonal antibodies and novel mechanisms. Its business model centers on in-licensing, co-development, and commercialization, aiming to grow into a global oncology leader by leveraging LG Chem's resources and strategic partnerships.
View full company profileTherapeutic Areas
Other HPV-negative Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Drugs
| Drug | Company | Phase |
|---|---|---|
| BCA101 | Bicara Therapeutics | Phase 1b/2 |